But results come from a curated dataset, with no in-trial comparator.

A common mutation comes into play for PRMT5 inhibition.

Tolerability could decide first-line therapy in EGFRm disease.

Investors now have more reasons to doubt Harmoni's ability to back US approval.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.